-
Mashup Score: 2
The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics. Researchers conducted two analyses to compare the cost of CGM use during a type 1 diabetes pregnancy with SMBG using finger sticks alone. In a base-case analysis in
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2
The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics. Researchers conducted two analyses to compare the cost of CGM use during a type 1 diabetes pregnancy with SMBG using finger sticks alone. In a base-case analysis in
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
👶Using a #CGM may lead to cost savings for pregnant women with type 1 #diabetes compared with self-monitoring blood glucose. Learn more ⬇️ @healiowomen @CUAnschutz https://t.co/aTxLqv1Jz6
-
-
Mashup Score: 0Q&A: Dexcom on forming partnerships and its CGM technology - 2 month(s) ago
Jake Leach, executive VP and chief operating officer at Dexcom, joined MobiHealthNews to discuss the company’s evolution and offerings beyond diabetes.
Source: www.mobihealthnews.comCategories: General Medicine News, General HCPsTweet-
Q&A: @Dexcom on forming partnerships and its #CGM technology | #diabetes https://t.co/uQxwXP75kE
-
-
Mashup Score: 0Study: Prescribing continuous glucose monitors under medical benefit may improve outcomes - 5 month(s) ago
If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may have lower costs, according to a new analysis. | If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may have lower costs, according to a new analysis.
Source: www.fiercehealthcare.comCategories: General Medicine News, General HCPsTweet-
Study: Prescribing continuous glucose monitors #CGM under medical benefit may improve outcomes | #diabetes https://t.co/yP6xYBl4ee
-
-
Mashup Score: 4FDA clears implantable CGM with sensor that lasts up to 1 year - 5 month(s) ago
The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release. The Eversense 365 (Senseonics and Ascensia Diabetes Care) is a CGM system that includes a sensor placed under the skin. The sensor lasts for up to 1 year, making the system the
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
🚨The Eversense 365, a #CGM system with an implantable sensor lasting up to 1 year, has received @US_FDA clearance for type 1 and type 2 #diabetes. Read more about this news ⬇️ @senseonics @AscensiaGlobal https://t.co/2Pj2oNoqNC
-
-
Mashup Score: 0Dexcom CGM worn in outer space on Polaris Dawn mission - 5 month(s) ago
Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn mission.
Source: www.drugdeliverybusiness.comCategories: General Medicine News, Future of MedicineTweet-
.@Dexcom #CGM worn in outer space on Polaris Dawn mission | #diabetes https://t.co/lRR7akQ0wi
-
-
Mashup Score: 1Ascensia’s new head of CGM talks plans for a 365-day sensor - 6 month(s) ago
Brian Hansen recently joined Ascensia, which markets Senseonics’ implantable glucose sensors. The current version lasts 180 days, but Senseonics is seeking FDA approval for a one-year sensor.
Source: www.medtechdive.comCategories: General Medicine News, General HCPsTweet-
.@AscensiaGlobal new head of #CGM talks plans for a 365-day @senseonics sensor | #diabetes https://t.co/Ruo1jcYB3Q
-
-
Mashup Score: 0
Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet-
Abbott @FreeStyleLibre Says Its Latest #CGM Sensor Is Its Most Discreet Yet - Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market | #diabetes https://t.co/xd2wku0KBz
-
-
Mashup Score: 0Dexcom CEO explains plans for Stelo CGM, G7 and beyond - 8 month(s) ago
Dexcom CEO Kevin Sayer says the prospect of an over-the-counter CGM made company leaders uneasy. He explained at ADA’s Scientific Sessions.
Source: www.massdevice.comCategories: General Medicine News, General HCPsTweet-
.@Dexcom CEO explains plans for Stelo #CGM, G7 and beyond | #diabetes https://t.co/hC229TRaG1
-
-
Mashup Score: 0Dexcom, Abbott benefit from non-insulin, basal CGM user increase - 10 month(s) ago
William Blair analyst Margaret Kaczor reported surprise at the increase in users of CGM within the non-insulin and basal insulin populations.
Source: www.drugdeliverybusiness.comCategories: General Medicine News, General HCPsTweet-
Non-insulin, basal #CGM use exceeds analysts’ expectations, @Dexcom and Abbott @FreeStyleLibre to benefit - nearly 300,000 new non-insulin CGM users, compared to a projection of 200,000 | #diabetes https://t.co/s93hRbNsoo
-
👶Using a #CGM may lead to cost savings for pregnant women with type 1 #diabetes compared with self-monitoring blood glucose. Learn more ⬇️ @healiowomen @CUAnschutz https://t.co/aTxLqv1Jz6